Email Alert | RSS    帮助

中国防痨杂志 ›› 2025, Vol. 47 ›› Issue (5): 613-622.doi: 10.19982/j.issn.1000-6621.20250004

• 论著 • 上一篇    下一篇

HPLC-MS/MS法同时测定血浆中贝达喹啉、普托马尼和利奈唑胺的方法学建立及应用

程文1, 朱慧2, 付雷1, 张炜焱1, 张立群3(), 陆宇1()   

  1. 1首都医科大学附属北京胸科医院耐药结核病研究北京市重点实验室/北京市结核病胸部肿瘤研究所药物研究室,北京 101149
    2首都医科大学附属北京胸科医院转化办公室,北京 101149
    3首都医科大学附属北京胸科医院结核科,北京 101149
  • 收稿日期:2024-12-31 出版日期:2025-05-10 发布日期:2025-04-29
  • 通信作者: 张立群,Email:zhang_liqun@gzlab.ac.cn;陆宇,Email:luyu4876@hotmail.com
  • 基金资助:
    北京市医院管理中心“登峰”人才培养计划(DFL20221402)

Development and application of an HPLC-MS/MS method for simultaneous determination of bedaquiline, pretomanid, and linezolid in plasma

Cheng Wen1, Zhu Hui2, Fu Lei1, Zhang Weiyan1, Zhang Liqun3(), Lu Yu1()   

  1. 1Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Department of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China
    2Office for the Scientific and Technological Achievements, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China
    3Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China
  • Received:2024-12-31 Online:2025-05-10 Published:2025-04-29
  • Contact: Zhang Liqun, Email: zhang_liqun@gzlab.ac.cn; Lu Yu, Email: luyu4876@hotmail.com
  • Supported by:
    Beijing Hospital Management Center’s “Peak” Talent Training Program(DFL20221402)

摘要: 【摘要】 目的: 建立同时测定血浆中贝达喹啉(Bdq)、普托马尼(Pa)、利奈唑胺(Lzd)药物浓度的液相色谱串联质谱法(HPLC-MS/MS),为临床治疗药物监测提供测定方法。方法: 血浆样品以普萘洛尔(propranolol, PR)为内标,使用乙腈沉淀血浆蛋白并离心取上清液。设置流动相为0.1%甲酸(A)和5mM甲酸铵的纯水与乙腈(B),采用梯度洗脱方式进行上清液中Bdq、Pa和Lzd浓度的HPLC-MS/MS分析。根据峰型和分离度确定色谱分离条件为柱温35℃、流速0.4ml/min、分析时间4min。质谱检测采用电喷雾离子源(ESI),在多反应监测(MRM)模式下进行正离子扫描。通过专属性、建立标准曲线与定量限测定、精密度与准确度、回收率与基质效应、稳定性考察对所建立的HPLC-MS/MS进行方法学考察,最后使用实验小鼠进行方法学建立与验证。结果: MRM模式扫描血浆样本结果显示:Bdq、Pa、Lzd和PR的去簇电压分别为80、91、80、100V,碎裂电压分别为80、32、28、30V,母离子/子离子分别为555.2/58.2、360.2/175.2、338.1/296.3和260.2/116.2。方法学考察结果显示,Bdq、Pa、Lzd的保留时间分别为1.93、1.79、1.53min,峰形良好,出峰位置均无干扰峰信号;线性相关系数(R2)分别为0.993、0.999和0.999,且分别在0.05~12.5、0.1~25、0.2~50μg/ml浓度范围内线性关系良好;3种药物的日内和日间准确度均在90%以上,精密度波动均小于15%;不同浓度的3种药物及内标PR的提取回收率达到78.45%~108.78%,受血浆处理方法的影响小,基质效应均高于90%,且符合±15%的要求;样品在不同储存条件下的稳定性误差均在±15%以内;应用该方法成功检测36份小鼠血浆样品中Bdq、Pa、Lzd的血药浓度范围分别为0.03~1.82、0.11~14.21、0.02~16.54μg/ml。结论: 本研究所建立的HPLC-MS/MS方法可稳定快速地同时检测血浆样本中Bdq、Pa和Lzd的药物浓度,方法学考察证实该方法稳定、准确、灵敏,可供临床参考应用。

关键词: 结核, 色谱法,液相, 质谱分析法, 剂量效应关系,药物, 贝达喹啉, 普托马尼, 利奈唑胺

Abstract:

Objective: To establish a high-performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS) method for simultaneous determination of the plasma concentrations of bedaquiline (Bdq), pretomanid (Pa), and linezolid (Lzd), providing a method for monitoring clinical therapeutic drugs. Methods: Plasma samples were precipitated using acetonitrile, meanwhile, propranolol (PR) was added as an internal standard, followed by centrifugation to obtain the supernatant. Using a gradient elution method for HPLC-MS/MS analysis of Bdq, Pa, and Lzd concentrations in the supernatant with mobile phases A (0.1% formic acid and 5 mM ammonium formate in water) and B (acetonitrile). Chromatographic separation conditions were determined based on peak shape and resolution with a column temperature of 35 ℃, flow rate of 0.4 ml/min, and analysis time of 4 min. Mass spectrometry detection was performed using an electrospray ionization source (ESI) in positive ion mode with multiple reaction monitoring (MRM). The established HPLC-MS/MS method was validated through specificity, standard curve establishment and limit of quantification determination, precision and accuracy, recovery and matrix effect, and stability studies. Finally, the method was applied and validated using experimental mice. Results: MRM mode scanning of plasma samples showed that the declustering voltages for Bdq, Pa, Lzd, and PR were 80, 91, 80, and 100 V, respectively, and the collision energies were 80, 32, 28, and 30 V, respectively, with parent ion/product ion pairs of 555.2/58.2, 360.2/175.2, 338.1/296.3, and 260.2/116.2, respectively. Methodological validation results showed that the retention times for Bdq, Pa, and Lzd were 1.93, 1.79, and 1.53 min, respectively, with good peak shapes and no interfering peaks signals at the elution positions; the linear correlation coefficients R2 were 0.993, 0.999, and 0.999, respectively, with good linear relationships in the concentration ranges of 0.05-12.5, 0.1-25, and 0.2-50 μg/ml, respectively; the intra-day and inter-day accuracies for the three drugs were above 90% and the precision fluctuations were less than 15%; the extraction recoveries of three drugs and the internal standard PR at different concentrations ranged from 78.45% to 108.78%. The method has the following characteristics: little affected by plasma processing methods. Matrix effects above 90%, meeting the ±15% requirement and stability errors under different storage conditions were within ±15%; the method successfully detected plasma concentrations of Bdq, Pa, and Lzd in 36 mouse plasma samples, with ranges of 0.03-1.82, 0.11-14.21, and 0.02-16.54 μg/ml, respectively. Conclusion: The established HPLC-MS/MS method can stably and rapidly detect the drug concentrations of Bdq, Pa, and Lzd in plasma samples simultaneously. Methodological validation showed that the method is stable, accurate, and sensitive. This method can serve as a reference for clinical application.

Key words: Tuberculosis, Chromatography, liquid, Mass spectrometry, Dose-response relationship, drug, Bedaquiline, Pretomanid, Linezolid

中图分类号: